Cantabio Pharmaceuticals, led by three Cambridge Judge Executive MBA (EMBA) graduates, announces licensing agreement with Cambridge Enterprise regarding novel therapeutic candidates for Alzheimer’s disease and Dementia.
Cantabio Pharmaceuticals, a company led by three alumni of the Executive MBA programme at Cambridge Judge Business School, announced a licensing agreement with Cambridge Enterprise that gives the company access to intellectual property from research targeting the Tau protein for the treatment of “Tauopathies” such as Alzheimer’s disease and Dementia.
Tauopathies refer to a certain class of neurodegenerative diseases related to the aggregation of tau protein in the brain, the most prevalent of which is Alzheimer’s disease.
Dr Gergely Tóth, Dr Thomas Sawyer and Simon Peace were classmates on the EMBA programme (2010) at the School, and developed the idea for Cantabio in 2015 after graduating. Gergely is Chief Executive Officer, Simon is Chief Financial Officer, and Thomas is Chief Operating Officer of Cantabio.
The new licensing agreement strengthens Cantabio’s portfolio of therapeutic programmes and its intellectual property in Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
Dr Tóth said:
This therapeutic programme represents a novel and innovative therapeutic approach for the treatment of Alzheimer’s and Dementia, which can also be applied to a number of other protein misfolding diseases. We are excited about the potential of this programme to combat Alzheimer’s disease and are especially pleased to have the opportunity to pursue ground-breaking research based on the licensed data and to further collaborate with leading researchers at the University of Cambridge.
Cantabio, based in Sunnyvale, California, focuses on developing and bringing novel drug candidates into clinical trials and beyond, for neurodegenerative disorders including Alzheimer’s and Parkinson’s diseases. Cambridge Enterprise, a subsidiary of the University of Cambridge, is responsible for the commercialisation of University intellectual property.